Please login to the form below

Not currently logged in
Email:
Password:

ASH meeting

This page shows the latest ASH meeting news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

At the American Society of Haematology (ASH) meeting last December, Bluebird reported results from a dose-escalation trial indicating that bb2121 was able to achieve an objective response rate of 94%

Latest news

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    This is despite some positive news for Juno released at the recent ASH meeting that another of its CAR T cell therapeutics, JCAR017, showed a 60% complete response in patients with ... As Juno wrestles with bad publicity and a depressed share price,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics